Intracellular Activation and Deactivation of Tasidotin, an Analog of Dolastatin 15: Correlation with Cytotoxicity

Tasidotin, an oncolytic drug in phase II clinical trials, is a peptide analog of the antimitotic depsipeptide dolastatin 15. In tasidotin, the carboxyl-terminal ester group of dolastatin 15 has been replaced by a carboxy-terminal tert-butyl amide. As expected from studies with cemadotin, [(3)H]tasid...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Bai, Ruoli, Edler, Michael C., Bonate, Peter L., Copeland, Terry D., Pettit, George R., Ludueña, Richard F., Hamel, Ernest
Format: Artigo
Idioma:Inglês
Publicat: American Society for Pharmacology and Experimental Therapeutics 2009
Matèries:
Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2635573/
https://ncbi.nlm.nih.gov/pubmed/18927208
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1124/mol.108.051110
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars